Literature DB >> 16600680

Serum antibody positivity for distinct Helicobacter pylori antigens in benign and malignant gastroduodenal disease.

Christian Schumann1, Kathy Triantafilou, F Maximilian Rasche, Angelika Möricke, Konstanze Vogt, Martha Triantafilou, Philipp Hahn, E Marion Schneider, Philipp M Lepper.   

Abstract

Infection with Helicobacter pylori may be associated with a variety of gastroduodenal diseases. Although H. pylori infection is common, peptic ulcer disease and gastric cancer occur in only a small minority of infected persons. This work was intended to correlate the pathological findings with the serological response to certain H. pylori antigens. Serum samples were taken from 285 patients who underwent gastroscopy. H. pylori infection was diagnosed by histology, culture or rapid urease test (RUT). Serum IgG reactivity against H. pylori-specific antigens was studied by Western blot. There was a significant association between the diagnosis of gastric cancer and the presence of IgG antibodies against the 19.5, 33 and 136 kDa (CagA) antigens. Comparing all H. pylori-positive patients with the gastric cancer group for the presence of the 19.5, 33 and 136 kDa (CagA) antigens, the results were as follows: chi2: 17.482, p < 0.001, power P = 0.994, odds ratio (OR) for the presence of gastric cancer: 19.5 (95% confidence interval (CI): 4.11-92.56). Antibodies against CagA alone or other bands (except 33 and 19.5 kDa antigens), as well as the age of patients were not related to a diagnosis of gastric cancer. Male patients were more likely to develop duodenal ulcer. IgG antibodies against the 19.5, 33 and 136 kDa (CagA) antigens could be helpful to identify patients at enhanced risk for the development of gastric cancer.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16600680     DOI: 10.1016/j.ijmm.2006.02.009

Source DB:  PubMed          Journal:  Int J Med Microbiol        ISSN: 1438-4221            Impact factor:   3.473


  7 in total

1.  Epitope peptides of Helicobacter pylori CagA antibodies from sera by whole-peptide mapping.

Authors:  Shamshul Ansari; Junko Akada; Yuichi Matsuo; Seiji Shiota; Yoko Kudo; Tadayoshi Okimoto; Kazunari Murakami; Yoshio Yamaoka
Journal:  J Gastroenterol       Date:  2019-05-02       Impact factor: 7.527

2.  Low frequency of cagA-positive Helicobacter pylori strains isolated from Iranian patients with MALT lymphoma.

Authors:  Amin Talebi Bezmin Abadi; Ali Ghasemzadeh; Ashraf Mohabati Mobarez
Journal:  Intern Emerg Med       Date:  2011-04-02       Impact factor: 3.397

3.  The impact of oral ciprofloxacin on the structure and functions of rat gastric mucosa.

Authors:  Nihal A Ibrahim; Kadreya E Elmorshedy; Doaa A Radwan; Manal A Buabeid
Journal:  Saudi J Biol Sci       Date:  2021-11-24       Impact factor: 4.052

4.  Serum antibodies positivity to 12 Helicobacter pylori virulence antigens in patients with benign or malignant gastroduodenal diseases--cross-sectional study.

Authors:  Tajana Filipec Kanizaj; Miroslava Katicić; Vladimir Presecki; Slavko Gasparov; Vesna Colić Cvrlje; Branko Kolarić; Anna Mrzljak
Journal:  Croat Med J       Date:  2009-04       Impact factor: 1.351

5.  Helicobacter pylori recombinant UreG protein: cloning, expression, and assessment of its seroreactivity.

Authors:  Akbar Khalilpour; Sabariah Osman; Muhammad Hafiznur Yunus; Amutha Santhanam; Nagarajan Vellasamy; Rahmah Noordin
Journal:  BMC Res Notes       Date:  2014-11-18

Review 6.  Non-invasive diagnostic tests for Helicobacter pylori infection.

Authors:  Lawrence Mj Best; Yemisi Takwoingi; Sulman Siddique; Abiram Selladurai; Akash Gandhi; Benjamin Low; Mohammad Yaghoobi; Kurinchi Selvan Gurusamy
Journal:  Cochrane Database Syst Rev       Date:  2018-03-15

7.  Correlations between the CagA Antigen and Serum Levels of Anti-Helicobacter pylori IgG and IgA in Children.

Authors:  Ji-Hyun Seo; Chun Woo Lim; Ji Sook Park; Jung Sook Yeom; Jae-Young Lim; Jin-Su Jun; Hyang-Ok Woo; Hee-Shang Youn; Seung-Chul Baik; Woo-Kon Lee; Myung-Je Cho; Kwang-Ho Rhee
Journal:  J Korean Med Sci       Date:  2016-02-17       Impact factor: 2.153

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.